National Cancer Institute · company speakers →
Dr. Nirali Shah will discuss the various forms of post-CAR T-cell relapse following CAR T-cell therapy in B-acute lymphoblastic leukemia (e.g., antigen positive/negative relapse and/or with lineage switch). She will review factors that may influence risk of relapse, such as baseline leukemia cytogenetics, CAR T-cell construct and disease burden, and how these risk factors may inform the relapse immunophenotype. Lastly, given the poor outcomes for patients with post CAR T-cell relapse, Dr. Shah will discuss therapeutic approaches which could be utilized for the prevention and/or treatment of relapse to improve long-term outcomes.
Is this you? Claim this profile →
No public contact links on file.
Sourcing speakers for your event?
Browse the speaker directory →